11/18
09:12 am
nito
N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination
Medium
Report
N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination
10/30
09:25 am
nito
N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers
Medium
Report
N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers
10/23
08:25 am
nito
N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
Low
Report
N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
10/8
12:30 pm
nito
N2OFF (NASDAQ:NITO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
N2OFF (NASDAQ:NITO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/8
09:25 am
nito
N2OFF regains compliance with Nasdaq minimum bid price requirement [Seeking Alpha]
Low
Report
N2OFF regains compliance with Nasdaq minimum bid price requirement [Seeking Alpha]
10/8
09:00 am
nito
N2OFF Regains Compliance with Nasdaq Minimum Bid Price Requirement
Medium
Report
N2OFF Regains Compliance with Nasdaq Minimum Bid Price Requirement
10/4
03:06 am
nito
Low
Report
9/29
04:24 pm
nito
SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer [Yahoo! Finance]
Medium
Report
SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer [Yahoo! Finance]